On the other hand, in MCF-7 cells activation of c-Src was quite efficiently prevented by FS-115 treatment (Supplementary Figure 1), suggesting that the spectrum of activity for this inhibitor may vary depending from the cancer subtypes. This evidence concerns the gene SRC and cancer.